Clinical Trials Search
Clinical Trial 19495
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT03271372
Phase: Phase III
Prinicipal Investigator: Andrew Brohl
Study Title
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
Summary
Objective
The primary objective of the trial is to compare the clinical activity of adjuvant avelumab to that of placebo, as determined by relapse]free survival in subjects with clinically detected nodal metastases from MCC after definitive therapy (surgery with/without adjuvant RT).
Therapies
Medications
Avelumab (); MSB00100718C (Avelumab); Placebo ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.